TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展

doi:10.11904/j.issn.1002-3070.2023.03.011

Abstract

Abstract: Non-small cell lung cancer(NSCLC)is the main cause of cancer-related deaths worldwide.Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is a standard first-line treatment for targeting epidermal growth factor receptor(EGFR)mutations in NSCLC patients.However,primary or acquired drug resistance leads to treatment interruption and disease progression.TP53 mutation is the most common type of co-mutation in patients with EGFR-mutant NSCLC.Many studies have shown that TP53-EGFR co-mutation indicates a poor prognosis for patients,and there is no consensus on treatment plan for patients with such mutations.This article reviews the prognostic value of TP53 mutation in patients with advanced EGFR-mutant NSCLC and the research progress of TP53-EGFR co-mutation in patients with advanced NSCLC.

Key words: Non-small cell lung cancer, TP53 Epidermal growth factor receptor co-mutation, Prognosis, Treatment

CLC Number:

R734.2

CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation[J]. Journal of Practical Oncology, 2023, 37(3): 262-266.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.03.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I3/262

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Chen P,Liu Y,Wen Y,et al.Non-small cell lung cancer in China[J].Cancer Commun(Lond),2022,42(10):937-970.
3 Fu K,Xie F,Wang F,et al.Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance[J].J Hematol Oncol,2022,15(1):173.
4 Johnson M,Garassino MC,Mok T,et al.Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors:Focus on novel therapies[J].Lung Cancer,2022,170:41-51.
5 Canale M,Andrikou K,Priano I,et al.The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer:clinical significance and implications for therapy[J].Cancers(Basel),2022,14(5):1143.
6 Roeper J,Christopoulos P,Falk M,et al.TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib[J].Transl Lung Cancer Res,2022,11(1):4-13.
7 Liu S,Yu J,Zhang H,et al.TP53 co-mutations in advanced EGFR-mutated non-small cell lung cancer:prognosis and therapeutic strategy for cancer therapy[J].Front Oncol,2022,12:860563.
8 Fan Z,Zhang Q,Feng L,et al.Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer[J].Ann Transl Med,2022,10(4):188.
9 Kennedy MC,Lowe SW.Mutant p53:it′s not all one and the same[J].Cell Death Differ,2022,29(5):983-987.
10 Vaddavalli PL,Schumacher B.The p53 network:cellular and systemic DNA damage responses in cancer and aging[J].Trends Genet,2022,38(6):598-612.
11 王蓉,潘思思,宋霞.晚期非小细胞肺癌EGFR-TP53共突变的研究进展[J].中国肺癌杂志,2022,25(3):174-182.
12 Passaro A,Attili I,Rappa A,et al.Genomic characterization of concurrent alterations in non-small cell lung cancer(NSCLC)harboring actionable mutations[J].Cancers(Basel),2021,13(9):2172.
13 Fu J,Tong Y,Xu Z,et al.Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy[J].Clin Lung Cancer,2023,24(1):29-39.
14 Canale M,Petracci E,Delmonte A,et al.Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors[J].Clin Cancer Res,2017,23(9):2195-2202.
15 Lan B,Zhao N,Du K,et al.Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs:an updated systematic review and meta-analysis[J].Oncol Lett,2022,24(5):384.
16 Li XM,Li WF,Lin JT,et al.Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung cancer treated with EGFR-TKI:analysis of a phase III randomized clinical trial(CTONG 0901)[J].Clin Lung Cancer,2021,22(2):100-109.
17 Yu R,Bai H,Li T,et al.TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib[J].Transl Oncol,2021,14(9):101163.
18 Le X,Molife C,Leusch MS,et al.TP53 co-mutation status association with clinical outcomes in patients with EGFR-mutant non-small cell lung cancer[J].Cancers(Basel),2022,14(24):6127.
19 Zhang C,Liu J,Xu D,et al.Gain-of-function mutant p53 in cancer progression and therapy[J].J Mol Cell Biol,2020,12(9):674-687.
20 Rho JK,Choi YJ,Ryoo BY,et al.P53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer[J].Cancer Res,2007,67(3):1163-1169.
21 Offin M,Chan JM,Tenet M,et al.Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes[J].J Thorac Oncol,2019,14(10):1784-1793.
22 Zheng C,Li X,Ren Y,et al.Coexisting EGFR and TP53 mutations in lung adenocarcinoma patients are associated with COMP and ITGB8 upregulation and poor prognosis[J].Front Mol Biosci,2020,7:30.
23 Vokes NI,Chambers E,Nguyen T,et al.Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J].J Thorac Oncol,2022,17(6):779-792.
24 Lopes-Coelho F,Martins F,Pereira SA,et al.Anti-angiogenic therapy:current challenges and future perspectives[J].Int J Mol Sci,2021,22(7):3765.
25 Li Y,Lin M,Wang S,et al.Novel angiogenic regulators and anti-angiogenesis drugs targeting angiogenesis signaling pathways:perspectives for targeting angiogenesis in lung cancer[J].Front Oncol,2022,12:842960.
26 Schwaederlé M,Lazar V,Validire P,et al.VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer:implications for antiangiogenesis therapy[J].Cancer Res,2015,75(7):1187-1190.
27 Wheler JJ,Janku F,Naing A,et al.TP53 alterations correlate with response to VEGF/VEGFR inhibitors:implications for targeted therapeutics[J].Mol Cancer Ther,2016,15(10):2475-2485.
28 Fang S,Cheng W,Zhang M,et al.Association of TP53 mutations with response to anlotinib treatment in advanced Non-Small Cell lung cancer[J].Onco Targets Ther,2020,13:6645-6650.
29 Cheng Y,Ma L,Liu Y,et al.Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors[J].Lung Cancer,2020,145:63-70.
30 Sun H,Ren P,Chen Y,et al.Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer:a real-world study[J].BMC Cancer,2023,23(1):198.
31 Nakagawa K,Nadal E,Garon EB,et al.RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer[J].Clin Cancer Res,2021,27(19):5258-5271.
32 Zhao H,Yao W,Min X,et al.Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC:the phase III ACTIVE study(CTONG1706)[J].J Thorac Oncol,2021,16(9):1533-1546.
33 商凯.EGFR-TKIs联合化疗一线治疗EGFR/TP53基因共突变晚期NSCLC的疗效及安全性观察[D].南昌:南昌大学,2022.
34 Yang Z,Chen Y,Wang Y,et al.Efficacy of EGFR-TKI plus chemotherapy or monotherapy as first-line treatment for advanced EGFR-mutant lung adenocarcinoma patients with co-mutations[J].Front Oncol,2021,11:681429.
35 Liu S,Geng S,Shi N,et al.Survival prediction of patients treated with immune checkpoint inhibitors via KRAS/TP53/EGFR-single gene mutation[J].Front Pharmacol,2022,13:878540.
36 Jin Y,Xue Q,Shen X,et al.PD-L1 expression and comprehensive molecular profiling predict survival in non-small cell lung cancer:a real-world study of a large chinese cohort[J].Clin Lung Cancer,2022,23(1):43-51.
37 Assoun S,Theou-Anton N,Nguenang M,et al.Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer[J].Lung Cancer,2019,132:65-71.
38 Lin X,Wang L,Xie X,et al.Prognostic biomarker TP53 mutations for immune checkpoint blockade therapy and its association with tumor microenvironment of lung adenocarcinoma[J].Front Mol Biosci,2020,7:602328.
39 Wang S,Xie T,Wang Y,et al.166P Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor(EGFR)-mutant lung adenocarcinoma patients[J].Ann Oncol,2022,33:S108.
40 Oxnard GR,Yang JC,Yu H,et al.TATTON:a multi-arm,phase Ib trial of osimertinib combined with selumetinib,savolitinib,or durvalumab in EGFR-mutant lung cancer[J].Ann Oncol,2020,31(4)507-516.
41 Chen Y,Chen Z,Chen R,et al.Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer[J].Future Oncol,2022,18(14):1757-1775.

[1]	CUI Yongkang, YU Chengping, XU Haozhi, MA Xinyu, MA Yong, LI Linqiang. Effects of nutritional risk index in predicting postoperative complications and prognosis of patients with resectable hepatocellular carcinoma [J]. Journal of Practical Oncology, 2023, 37(3): 243-251.
[2]	XU Ting, CHENG Hua, ZHANG Wei. Research progress in the early diagnosis and minimally invasive surgical treatment of elderly pancreatic cancer [J]. Journal of Practical Oncology, 2023, 37(3): 257-261.
[3]	LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation [J]. Journal of Practical Oncology, 2023, 37(2): 117-122.
[4]	ZHANG Yidan, ZHONG Rui, SUN Zhenxuan, WANG Teng, LIU Jintao. Research progress of SYT13 in cancer [J]. Journal of Practical Oncology, 2023, 37(2): 181-184.
[5]	WEN Shichao, WANG Jingxuan. Research status of copper-dependent cell death and copper in breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 185-189.
[6]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[7]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[8]	SUN Xinglu, CHEN Che. Research progress of Egr1 in liver cancer [J]. Journal of Practical Oncology, 2022, 36(5): 435-439.
[9]	WANG Xinghan, LV Yalei. Mechanisms of trastuzumab resistance and post-resistance treatment strategies in HER2-positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 445-451.
[10]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[11]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[12]	LI Bo, PENG Xiaolin, WANG Shanshan, LI Gairui, ZHAO Dan, PENG Ji. Comparative study on application effect of two risk assessment models in screening colorectal cancer [J]. Journal of Practical Oncology, 2022, 36(3): 197-202.
[13]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[14]	WANG Hongying, LI Yan, HAN Xinhao, WEI Xiaoli, JIA Huixun, YUAN Wenjuan, ZHANG Qiuju. Construction and validation of a risk model for early diagnosis and prognosis of gastric cancer based on immune-related lncRNAs [J]. Journal of Practical Oncology, 2022, 36(2): 119-126.
[15]	YIN Yi, OU Chaoyang, HE Aiqin. Expression of GAB2 in ovarian cancer and its correlation with prognosis [J]. Journal of Practical Oncology, 2022, 36(2): 150-155.

Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments